Bacterial Meningitis Treatments

Find Bacterial Meningitis Treatments

Brand Name

Meropenem

View Brand Information
FDA approval date: October 14, 2011
Classification: Penem Antibacterial
Form: Injection

What is Meropenem?

Meropenem for injection is a penem antibacterial indicated for the treatment of: Complicated skin and skin structure infections .

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Optimization of Beta-lactam Dosing in Critically Ill Patients With Suspected or Documented Antimicrobial Resistant Gram-Negative Infections With Cystatin-C (OPTIMIZE-GNI)
Optimization of Beta-lactam Dosing in Critically Ill Patients With Suspected or Documented Antimicrobial Resistant Gram-Negative Infections With Cystatin-C (OPTIMIZE-GNI)
Enrollment Status: Recruiting
Publish Date: June 12, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: This is a Phase 4, interventional, multi-center pharmacokinetics (PK) study in up to 200 adult patients who are residing in an ICU. This study will compare the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the PK profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE), and io...

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial
Enrollment Status: Recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Phase: Not Applicable

Summary: This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the cholangitis rate in BA patients who received prophylactic oral antibiotics and those who did not. The patients were followed up for 2 years after KP.

Comparing Efficacy of Intravenous Azithromycin and Meropenem for Extensively Drug-Resistant Enteric Fever: A Randomized Controlled Trial (Pilot Study)
Comparing Efficacy of Intravenous Azithromycin and Meropenem for Extensively Drug-Resistant Enteric Fever: A Randomized Controlled Trial (Pilot Study)
Enrollment Status: Recruiting
Publish Date: May 08, 2026
Intervention Type: Drug
Study Phase: Phase 4

Objective: o To evaluate the efficacy of intravenous azithromycin compared with meropenem in the treatment of extensively drug-resistant (XDR) enteric fever. 2. Secondary

View All Clinical Trials

Related Latest Advances

External validation of the population pharmacokinetic model of meropenem in patients undergoing neonatal extracorporeal membrane oxygenation and continuous renal replacement therapy.
External validation of the population pharmacokinetic model of meropenem in patients undergoing neonatal extracorporeal membrane oxygenation and continuous renal replacement therapy.
Journal: Perfusion
Published: June 23, 2026
An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens.
An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens.
Journal: Expert opinion on drug metabolism & toxicology
Published: June 19, 2026
Microbiological Profile and Antibiotic Sensitivity Pattern of Bile Culture in Patients Undergoing Laparoscopic Cholecystectomy for Cholelithiasis in Tertiary Care Hospital.
Microbiological Profile and Antibiotic Sensitivity Pattern of Bile Culture in Patients Undergoing Laparoscopic Cholecystectomy for Cholelithiasis in Tertiary Care Hospital.
Journal: Kathmandu University medical journal (KUMJ)
Published: June 19, 2026
View All Latest Advances